M Victoria Cachofeiro

List of Publications by Year
in descending order

119 papers	4,742 citations	94433 37 h-index	114465 63 g-index
125 all docs	125 docs citations	125 times ranked	6636 citing authors

#	Article	IF	Citations
1	Microsomal prostaglandin E synthaseâ€1 is involved in the metabolic and cardiovascular alterations associated with obesity. British Journal of Pharmacology, 2022, 179, 2733-2753.	5.4	6
2	Oxidative Stress in Obesity. Antioxidants, 2022, 11, 639.	5.1	8
3	Angiotensin II Promotes Skeletal Muscle Angiogenesis Induced by Volume-Dependent Aerobic Exercise Training: Effects on miRNAs-27a/b and Oxidantâ€“Antioxidant Balance. Antioxidants, 2022, 11, 651.	5.1	1
4	Mitochondrial Oxidative Stress Promotes Cardiac Remodeling in Myocardial Infarction through the Activation of Endoplasmic Reticulum Stress. Antioxidants, 2022, 11, 1232.	5.1	5
5	Role of endoplasmic reticulum stress in renal damage after myocardial infarction. Clinical Science, 2021, 135, 143-159.	4.3	3
6	Oxidative Stress and Vascular Damage in the Context of Obesity: The Hidden Guest. Antioxidants, 2021, 10, 406.	5.1	13
7	Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved. Cells, 2021, 10, 1824.	4.1	13
8	The Interplay of Mitochondrial Oxidative Stress and Endoplasmic Reticulum Stress in Cardiovascular Fibrosis in Obese Rats. Antioxidants, 2021, 10, 1274.	5.1	21
9	The Interaction between Mitochondrial Oxidative Stress and Gut Microbiota in the Cardiometabolic Consequences in Diet-Induced Obese Rats. Antioxidants, 2020, 9, 640.	5.1	23
10	Identification of a Plasma Microrna Signature as Biomarker of Subaneurysmal Aortic Dilation in Patients with High Cardiovascular Risk. Journal of Clinical Medicine, 2020, 9, 2783.	2.4	10
11	Secreted Phospholipase A2-IIA Modulates Transdifferentiation of Cardiac Fibroblast through EGFR Transactivation: An Inflammationâ€“Fibrosis Link. Cells, 2020, 9, 396.	4.1	15
12	The Crosstalk between Cardiac Lipotoxicity and Mitochondrial Oxidative Stress in the Cardiac Alterations in Diet-Induced Obesity in Rats. Cells, 2020, 9, 451.	4.1	24
13	The role of mitochondrial oxidative stress in the metabolic alterations in dietâ€induced obesity in rats. FASEB Journal, 2019, 33, 12060-12072.	0.5	28
14	Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. Biomolecules, 2019, 9, 610.	4.0	39
15	The Impact of Cardiac Lipotoxicity on Cardiac Function and Mirnas Signature in Obese and Non-Obese Rats with Myocardial Infarction. Scientific Reports, 2019, 9, 444.	3.3	19
16	Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. Clinical Science, 2018, 132, 1471-1485.	4.3	37
17	Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	28
18	Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12. Scientific Reports, 2018, 8, 6801.	3.3	22

#	Article	IF	Citations
19	The impact of obesity in the cardiac lipidome and its consequences in the cardiac damage observed in obese rats. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 10-20.	0.2	0
20	A role for fumarate hydratase in mediating oxidative effects of galectin-3 in human cardiac fibroblasts. International Journal of Cardiology, 2018, 258, 217-223.	1.7	17
21	Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. Journal of Hypertension, 2018, 36, 368-376.	0.5	34
22	The impact of obesity in the cardiac lipidome and its consequences in the cardiac damage observed in obese rats. ClÃ¬nica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 10-20.	0.8	3
23	mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress. Hypertension, 2018, 72, 492-502.	2.7	29
24	High levels of circulating TNFR1 increase the risk of allâ€cause mortality and progression of renal disease in type 2 diabetic nephropathy. Nephrology, 2017, 22, 354-360.	1.6	16
25	A role for galectin-3Âin the development of early molecular alterations in short-term aortic stenosis. Clinical Science, 2017, 131, 935-949.	4.3	19
26	The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity. Scientific Reports, 2017, 7, 16802.	3.3	32
27	Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage. PLoS ONE, 2016, 11, e0166272.	2.5	43
28	Role for Galectinâ€3 in Calcific Aortic Valve Stenosis. Journal of the American Heart Association, 2016, 5, .	3.7	55
29	Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. Cardiovascular Diabetology, 2016, 15, 155.	6.8	37
30	The lysyl oxidase inhibitor (Î²-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats. Journal of Molecular and Cellular Cardiology, 2016, 92, 96-104.	1.9	52
31	Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension, 2015, 66, 767-775.	2.7	129
32	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. Molecular and Cellular Endocrinology, 2015, 411, 20-27.	3.2	26
33	Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity. Hypertension, 2015, 66, 961-969.	2.7	68
34	The lysyl oxidase inhibitor Î²-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats. DMM Disease Models and Mechanisms, 2015, 8, 543-551.	2.4	40
35	The Impact of Galectin-3 Inhibition onÂAldosterone-Induced Cardiac and RenalÂInjuries. JACC: Heart Failure, 2015, 3, 59-67.	4.1	164
36	Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress. Journal of Hypertension, 2014, 32, 1104-1114.	0.5	107

#	Article	IF	Citations
37	The endocrine and cardiovascular systems: a close liaison. Hormone Molecular Biology and Clinical Investigation, 2014, 18, 1-2.	0.7	10
38	Antagonistic effect of TNF-alpha and insulin on uncoupling protein 2 (UCP-2) expression and vascular damage. Cardiovascular Diabetology, 2014, 13, 108.	6.8	13
39	Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 67-75.	2.4	312
40	Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. Toxicology and Applied Pharmacology, 2013, 268, 188-200.	2.8	49
41	Effect of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial. American Journal of Kidney Diseases, 2013, 61, 211-218.	1.9	70
42	Aerobic exercise reduces oxidative stress and improves vascular changes of small mesenteric and coronary arteries in hypertension. British Journal of Pharmacology, 2013, 168, 686-703.	5.4	119
43	Left and Right Ventricle Late Remodeling Following Myocardial Infarction in Rats. PLoS ONE, 2013, 8, e64986.	2.5	54
44	A Role for Soluble ST2 in Vascular Remodeling Associated with Obesity in Rats. PLoS ONE, 2013, 8, e79176.	2.5	37
45	The Effects of Adiponectin and Leptin on Human Endothelial Cell Proliferation: A Live-Cell Study. Journal of Vascular Research, 2012, 49, 111-122.	1.4	12
46	Cardiotrophin-1 induces sarcoplasmic reticulum Ca2+ leak and arrhythmogenesis in adult rat ventricular myocytes. Cardiovascular Research, 2012, 96, 81-89.	3.8	22
47	The impact of bariatric surgery on renal and cardiac functions in morbidly obese patients. Nephrology Dialysis Transplantation, 2012, 27, iv53-iv57.	0.7	22
48	Papel de la quinasa regulada por suero y glucocorticoides 1 en las alteraciones cardiacas producidas por la aldosterona en ratas. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2012, 24, 267-274.	0.8	0
49	Modificaciones anatomofuncionales del corazÃ³n en la obesidad mÃ³rbida. Cambios tras la cirugÃa bariÃ¡trica. Revista Espanola De Cardiologia, 2012, 65, 14-21.	1.2	56
50	HipertensiÃ³n portal: desarrollo de una respuesta inflamatoria sistÃ©mica asociada a sÃndrome metabÃ³lico. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2012, 24, 157-166.	0.8	0
51	Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serumâ€and glucocorticoidâ€regulated kinase type 1. Experimental Physiology, 2012, 97, 710-718.	2.0	14
52	Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: A novel anti-atherosclerotic mechanism. Pharmacological Research, 2012, 66, 536-543.	7.1	32
53	Brown Fat Lipoatrophy and Increased Visceral Adiposity through a Concerted Adipocytokines Overexpression Induces Vascular Insulin Resistance and Dysfunction. Endocrinology, 2012, 153, 1242-1255.	2.8	28
54	A wound-like inflammatory aortic response in chronic portal hypertensive rats. Molecular Immunology, 2012, 51, 177-187.	2.2	8

#	Article	IF	Citations
55	DIOL Triterpenes Block Profibrotic Effects of Angiotensin II and Protect from Cardiac Hypertrophy. PLoS ONE, 2012, 7, e41545.	2.5	22
56	Efecto del tratamiento con candesartan sobre los mecanismos y factores implicados en el desarrollo de la enfermedad cardiovascular asociada a sobrepeso y exceso de tejido adiposo visceral en la rata. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2011, 23, 55-61.	0.8	0
57	Structural, Functional, and Molecular Alterations Produced by Aldosterone Plus Salt in Rat Heart: Association With Enhanced Serum and Glucocorticoidâ€“regulated Kinase-1 Expression. Journal of Cardiovascular Pharmacology, 2011, 57, 114-121.	1.9	19
58	Cardiac benefits of exercise training in aging spontaneously hypertensive rats. Journal of Hypertension, 2011, 29, 2349-2358.	0.5	47
59	Rosuvastatin restored adrenergic and nitrergic function in mesenteric arteries from obese rats. British Journal of Pharmacology, 2011, 162, 271-285.	5.4	27
60	Endothelial dysfunction of rat coronary arteries after exposure to low concentrations of mercury is dependent on reactive oxygen species. British Journal of Pharmacology, 2011, 162, 1819-1831.	5.4	64
61	Exposure to low mercury concentration in vivo impairs myocardial contractile function. Toxicology and Applied Pharmacology, 2011, 255, 193-199.	2.8	24
62	Interplay of Hypertension, Inflammation, and Angiotensin II. American Journal of Hypertension, 2011, 24, 1059-1059.	2.0	8
63	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H2372-H2382.	3.2	56
64	A Proteomic Approach to Determine Changes in Proteins Involved in the Myocardial Metabolism in Left Ventricles of Spontaneously Hypertensive Rats. Cellular Physiology and Biochemistry, 2010, 25, 347-358.	1.6	23
65	Aldosterone and the cardiovascular system: a dangerous association. Hormone Molecular Biology and Clinical Investigation, 2010, 4, 539-48.	0.7	2
66	Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes. Cardiovascular Research, 2010, 87, 459-466.	3.8	33
67	The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. International Journal of Cardiology, 2010, 139, 32-41.	1.7	44
68	Papel de las estatinas en la enfermedad renal crÃ³nica (ERC). ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2010, 22, 17-24.	0.8	0
69	Response to â€˜Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular diseaseâ€™. Kidney International, 2009, 75, 1355.	5.2	0
70	Inflammation: A Link Between Hypertension and Atherosclerosis. Current Hypertension Reviews, 2009, 5, 40-48.	0.9	25
71	Urocortin induces positive inotropic effect in rat heart. Cardiovascular Research, 2009, 83, 717-725.	3.8	37
72	Inflammation but Not Endothelial Dysfunction Is Associated with the Severity of Coronary Artery Disease in Dyslipidemic Subjects. Mediators of Inflammation, 2009, 2009, 1-8.	3.0	28

#	Article	IF	Citations
73	Cardiac Lâ€type calcium current is increased in a model of hyperaldosteronism in the rat. Experimental Physiology, 2009, 94, 675-683.	2.0	20
74	The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptinâ€“adiponectin imbalance. Journal of Hypertension, 2009, 27, S37-S41.	0.5	22
75	Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: A 12-week, multicenter, randomized, open-label, parallel-group study. Clinical Therapeutics, 2008, 30, 84-97.	2.5	18
76	Aldosterone and the vascular system. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 331-335.	2.5	66
77	ParticipaciÃ³n de los mineralocorticoides en la respuesta inflamatoria vascular asociada a la hipertensiÃ³n. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2008, 20, 233-238.	0.8	0
78	Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney International, 2008, 74, S4-S9.	5.2	491
79	Specific Amelioration of Cerebral Endothelial Dysfunction in Hypertensive Patients Treated With Atorvastatin. American Journal of Hypertension, 2008, 21, 604-604.	2.0	1
80	Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H211-H219.	3.2	47
81	Fenofibrate and Pioglitazone Do Not Ameliorate the Altered Vascular Reactivity in Aorta of Isoproterenol-treated Rats. Journal of Cardiovascular Pharmacology, 2008, 52, 413-421.	1.9	6
82	Endothelial Dysfunction, Oxidative Stress and Inflammation in Atherosclerosis: Beneficial Effects of Statins. Current Medicinal Chemistry, 2007, 14, 243-248.	2.4	145
83	Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. Journal of Hypertension, 2007, 25, 629-638.	0.5	33
84	Papel del factor de crecimiento de tejido conectivo en el daÃ±o vascular asociado a hipertensiÃ³n en ratas. InteracciÃ³n con la aldosterona. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2007, 19, 232-239.	0.8	0
85	Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, S206-S212.	6.1	97
86	Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, S231-S235.	6.1	86
87	Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 192-200.	1.7	27
88	Oxidative Stress in Uremia. Journal of the American Society of Nephrology: JASN, 2006, 17, S174-S177.	6.1	38
89	Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFÎºB/IÎºB system. Journal of Hypertension, 2005, 23, 1167-1172.	0.5	50
90	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney International, 2005, 67, S3-S9.	5.2	13

#	Article	IF	Citations
91	Effect of Recombinant Human Growth Hormone Administration on Body Composition and Vascular Function and Structure in Old Male Wistar Rats. Biogerontology, 2005, 6, 303-312.	3.9	24
92	Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-Î²B/IÎ²B system. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H111-H115.	3.2	114
93	Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats. Hypertension, 2005, 46, 107-112.	2.7	115
94	Eplerenone Reduces Oxidative Stress and Enhances eNOS in SHR: Vascular Functional and Structural Consequences. Antioxidants and Redox Signaling, 2005, 7, 1294-1301.	5.4	66
95	Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide. Regulatory Peptides, 2004, 120, 253-260.	1.9	28
96	Chronic l-arginine treatment reduces vascular smooth muscle cell hypertrophy through cell cycle modifications in spontaneously hypertensive rats. Journal of Hypertension, 2004, 22, 751-758.	0.5	11
97	Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits. Clinical Science, 2003, 104, 357-365.	4.3	9
98	Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits. Clinical Science, 2003, 104, 357.	4.3	11
99	Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clinical Science, 2003, 105, 655-662.	4.3	26
100	Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2003, 285, R674-R681.	1.8	39
101	Renal Dysfunction After Chronic Blockade of Nitric Oxide Synthesis. Antioxidants and Redox Signaling, 2002, 4, 885-891.	5.4	7
102	Valsartan improves fibrinolytic balance in atherosclerotic rabbits. Journal of Hypertension, 2002, 20, 303-310.	0.5	28
103	Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension. Kidney International, 2002, 62, S2-S7.	5.2	19
104	Relevance of endothelium-derived hyperpolarizing factor in the effects of hypertension on rat coronary relaxations. Journal of Hypertension, 2001, 19, 539-545.	0.5	30
105	Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits. General Pharmacology, 2000, 34, 263-272.	0.7	17
106	The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 545-554.	2.8	14
107	AT1Receptor Antagonism Reduces Endothelial Dysfunction and Intimal Thickening in Atherosclerotic Rabbits. Hypertension, 1999, 34, 969-975.	2.7	79
108	Effects of antihypertensive therapy on factors mediating endothelium-dependent relaxation in rats treated chronically with L-NAME. Journal of Hypertension, 1999, 17, 221-227.	0.5	29

#	Article	IF	Citations
109	In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess. Molecular and Cellular Biochemistry, 1998, 185, 177-182.	3.1	17
110	Factors involved in the effects of losartan on endothelialdysfunction induced by aging in SHR. Kidney International, 1998, 54, S30-S35.	5.2	18
111	Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. Journal of Hypertension, 1998, 16, 665-672.	0.5	27
112	Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats. Journal of Hypertension, 1997, 15, 1677-1684.	0.5	31
113	Endothelial dysfunction in spontaneously hypertensive rats. Journal of Hypertension, 1997, 15, 613-618.	0.5	95
114	Nitric Oxide, the Kidney, and Hypertension. American Journal of Hypertension, 1997, 10, 129-140.	2.0	61
115	Renal and Vascular Consequences of the Chronic Nitric Oxide Synthase Inhibition*Effects of Antihypertensive Drugs. American Journal of Hypertension, 1996, 9, 1077-1083.	2.0	40
116	Losartan Reduces Phenylephrine Constrictor Response in Aortic Rings From Spontaneously Hypertensive Rats. Hypertension, 1996, 28, 967-972.	2.7	54
117	Nitric Oxide and Prostaglandins in the Prolonged Effects of Losartan and Ramipril in Hypertension. Hypertension, 1995, 26, 236-243.	2.7	53
118	Molecular Heterogeneity of Circulating Prolactin in Chronic Uremic Men and Renal Transplant Recipients*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 352-356.	3.6	12
119	Mineralocorticoid Receptor and Leptin: A Dangerous Liaison in the Obese Heart. , 0, , .		0